S. Michael Rothenberg

S. Michael Rothenberg

Auto-generated profile, based on publicly available information

S. Michael Rothenberg

Pfizer Boulder Research and Development, Boulder, Colorado. 11

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
ADAlexander Drilon
Alexander Drilon
MSManish R. Sharma
Manish R. Sharma
MJMelissa L. Johnson
Melissa L. Johnson
TYTimothy A. Yap
Timothy A. Yap
SGShirish M. Gadgeel
Shirish M. Gadgeel
SRS. Michael Rothenberg
S. Michael Rothenberg
Rationally targeted therapies have transformed cancer treatment, but many patients develop resistance through bypass signaling pathway activation. PF-07284892 (ARRY-558) is an allosteric SHP2 inhibitor designed to overcome bypass-signaling-mediated resistance when combined with inhibitors of various oncogenic drivers. Activity in this setting was confirmed in diverse tumor models. Patients with ALK fusion–positive lung cancer, BRAFV600E-mutant colorectal cancer, KRASG12D-mutant ovarian cancer, and ROS1 fusion–positive pancreatic cancer who previously developed targeted therapy resistance were treated with PF-07284892 on the first dose level of a first-in-human clinical trial. After progression on PF-07284892 monotherapy, a novel study design allowed the addition of oncogene-directed targeted therapy that had previously failed. Combination therapy led to rapid tumor and circulating tumor DNA (ctDNA) responses and extended the duration of overall clinical benefit. Significance: PF-07284892–targeted therapy combinations overcame bypass-signaling-mediated resistance in a clinical setting in which neither component was active on its own. This provides proof of concept of the utility of SHP2 inhibitors in overcoming resistance to diverse targeted therapies and provides a paradigm for accelerated testing of novel drug combinations early in clinical development. See related commentary by Hernando-Calvo and Garralda, p. 1762. This article is highlighted in the In This Issue feature, p. 1749

1 May 2024 in Cancer Discovery
Verified
Journal Article
Open access
RYRona Yaeger
Rona Yaeger
MMMeredith A. McKean
Meredith A. McKean
RHRizwan Haq
Rizwan Haq
JBJ. Thaddeus Beck
J. Thaddeus Beck
MTMatthew H. Taylor
Matthew H. Taylor
SRS. Michael Rothenberg
S. Michael Rothenberg
RAF inhibitors have transformed treatment for patients with BRAFV600-mutant cancers, but clinical benefit is limited by adaptive induction of ERK signaling, genetic alterations that induce BRAFV600 dimerization, and poor brain penetration. Next-generation pan-RAF dimer inhibitors are limited by a narrow therapeutic index. PF-07799933 (ARRY-440) is a brain-penetrant, selective, pan-mutant BRAF inhibitor. PF-07799933 inhibited signaling in vitro, disrupted endogenous mutant-BRAF:wild-type-CRAF dimers, and spared wild-type ERK signaling. PF-07799933 ± binimetinib inhibited growth of mouse xenograft tumors driven by mutant BRAF that functions as dimers and by BRAFV600E with acquired resistance to current RAF inhibitors. We treated patients with treatment-refractory BRAF-mutant solid tumors in a first-in-human clinical trial (NCT05355701) that utilized a novel, flexible, pharmacokinetics-informed dose escalation design that allowed rapid achievement of PF-07799933 efficacious concentrations. PF-07799933 ± binimetinib was well-tolerated and resulted in multiple confirmed responses, systemically and in the brain, in patients with BRAF-mutant cancer who were refractory to approved RAF inhibitors. Significance: PF-07799933 treatment was associated with antitumor activity against BRAFV600- and non-V600-mutant cancers preclinically and in treatment-refractory patients, and PF-07799933 could be safely combined with a MEK inhibitor. The novel, rapid pharmacokinetics (PK)-informed dose escalation design provides a new paradigm for accelerating the testing of next-generation targeted therapies early in clinical development.

4 August 2023
Verified
Other
Open access
ADAlexander Drilon
Alexander Drilon
MSManish R. Sharma
Manish R. Sharma
MJMelissa L. Johnson
Melissa L. Johnson
TYTimothy A. Yap
Timothy A. Yap
SGShirish M. Gadgeel
Shirish M. Gadgeel
SRS. Michael Rothenberg
S. Michael Rothenberg
Supplementary Table 1: X-ray crystallography data collection and refinement statistics

11 December 2025
Verified
Other
Open access
ADAlexander Drilon
Alexander Drilon
MSManish R. Sharma
Manish R. Sharma
MJMelissa L. Johnson
Melissa L. Johnson
TYTimothy A. Yap
Timothy A. Yap
SGShirish M. Gadgeel
Shirish M. Gadgeel
SRS. Michael Rothenberg
S. Michael Rothenberg
Supplementary Table 1: X-ray crystallography data collection and refinement statistics

11 December 2025
Verified
Other
Open access
ADAlexander Drilon
Alexander Drilon
MSManish R. Sharma
Manish R. Sharma
MJMelissa L. Johnson
Melissa L. Johnson
TYTimothy A. Yap
Timothy A. Yap
SGShirish M. Gadgeel
Shirish M. Gadgeel
SRS. Michael Rothenberg
S. Michael Rothenberg
Supplementary Figure 4: PF-07284892 combination efficacy in additional oncogenic driver-positive mouse cancer models and monotherapy PK/PD

11 December 2025
Verified
Other
Open access
ADAlexander Drilon
Alexander Drilon
MSManish R. Sharma
Manish R. Sharma
MJMelissa L. Johnson
Melissa L. Johnson
TYTimothy A. Yap
Timothy A. Yap
SGShirish M. Gadgeel
Shirish M. Gadgeel
SRS. Michael Rothenberg
S. Michael Rothenberg
Supplementary Figure 7: PF-07284892 sensitizes a patient with GOPC-ROS1 fusion-positive pancreatic cancer to lorlatinib